Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

MV Mateos; Pieter Sonneveld; V Hungria; AK Nooka; JA Estell; W Barreto; P Corradini; CK Min; E Medvedova; K Weisel; C Chiu; JM Schecter; H Amin; X Qin; J Ukropec; R Kobos; A Spencer

doi:10.1016/j.clml.2019.09.623

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

MV Mateos, Pieter Sonneveld, V Hungria, AK Nooka, JA Estell, W Barreto, P Corradini, CK Min, E Medvedova, K Weisel, C Chiu, JM Schecter, H Amin, X Qin, J Ukropec, R Kobos, A Spencer

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

121 Citations (Scopus)

13 Downloads (Pure)

Original language	English
Pages (from-to)	509-518
Number of pages	10
Journal	Clinical Lymphoma Myeloma & Leukemia
Volume	20
Issue number	8
DOIs	https://doi.org/10.1016/j.clml.2019.09.623
Publication status	Published - 2020

Research programs

EMC OR-01

Access to Document

10.1016/j.clml.2019.09.623

Repub_127538_O-A.pdfFinal published version, 714 KB

Cite this

Mateos, MV., Sonneveld, P., Hungria, V., Nooka, AK., Estell, JA., Barreto, W., Corradini, P., Min, CK., Medvedova, E., Weisel, K., Chiu, C., Schecter, JM., Amin, H., Qin, X., Ukropec, J., Kobos, R., & Spencer, A. (2020). Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical Lymphoma Myeloma & Leukemia, 20(8), 509-518. https://doi.org/10.1016/j.clml.2019.09.623

@article{f8b04f05c5f643748e5a30cfd7c0d469,

title = "Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR",

author = "MV Mateos and Pieter Sonneveld and V Hungria and AK Nooka and JA Estell and W Barreto and P Corradini and CK Min and E Medvedova and K Weisel and C Chiu and JM Schecter and H Amin and X Qin and J Ukropec and R Kobos and A Spencer",

year = "2020",

doi = "10.1016/j.clml.2019.09.623",

language = "English",

volume = "20",

pages = "509--518",

journal = "Clinical Lymphoma Myeloma & Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "8",

}

Mateos, MV, Sonneveld, P, Hungria, V, Nooka, AK, Estell, JA, Barreto, W, Corradini, P, Min, CK, Medvedova, E, Weisel, K, Chiu, C, Schecter, JM, Amin, H, Qin, X, Ukropec, J, Kobos, R & Spencer, A 2020, 'Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR', Clinical Lymphoma Myeloma & Leukemia, vol. 20, no. 8, pp. 509-518. https://doi.org/10.1016/j.clml.2019.09.623

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. / Mateos, MV; Sonneveld, Pieter; Hungria, V et al.
In: Clinical Lymphoma Myeloma & Leukemia, Vol. 20, No. 8, 2020, p. 509-518.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

AU - Mateos, MV

AU - Sonneveld, Pieter

AU - Hungria, V

AU - Nooka, AK

AU - Estell, JA

AU - Barreto, W

AU - Corradini, P

AU - Min, CK

AU - Medvedova, E

AU - Weisel, K

AU - Chiu, C

AU - Schecter, JM

AU - Amin, H

AU - Qin, X

AU - Ukropec, J

AU - Kobos, R

AU - Spencer, A

PY - 2020

Y1 - 2020

U2 - 10.1016/j.clml.2019.09.623

DO - 10.1016/j.clml.2019.09.623

M3 - Article

C2 - 32482541

SN - 2152-2650

VL - 20

SP - 509

EP - 518

JO - Clinical Lymphoma Myeloma & Leukemia

JF - Clinical Lymphoma Myeloma & Leukemia

IS - 8

ER -